ArticleBMC endocrine disorders2026
Reference interval of parathyroid hormone based on the Korea National Health and Nutrition Examination Survey 2024.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParathyroid hormone (PTH) plays a pivotal role in calcium–phosphate metabolism and bone health; however, interpretation of PTH concentrations remains challenging because of biological variability and substantial analytical heterogeneity among assays. In Korea, population-based data on PTH reference intervals are limited, and assay-specific reference intervals have not been well established.
methodsWe evaluated the reference interval of serum PTH using data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2024. A stepwise, biologically informed selection process was applied to define reference populations by progressively excluding participants with conditions known to influence PTH metabolism, including impaired renal function, vitamin D insufficiency, and abnormalities in mineral-related biochemical parameters (calcium, magnesium, phosphate, and alkaline phosphatase).
resultsAmong the 6,997 participants in the KNHANES 2024 dataset, serum PTH measurements were available for 4,502 adults aged ≥ 40 years. The high prevalence of supplement use and age-restricted sampling limited the size of suitable reference populations. The number of survey-design–valid participants frequently fell below the recommended threshold for reference interval estimation (< 120) after applying criteria for vitamin D sufficiency, mineral homeostasis, and age- and sex-specific alkaline phosphatase. Among 155 participants without a history of disease, not using dietary supplements, not pregnant, and with an estimated glomerular filtration rate ≥ 60 mL/min/1.73 m², the unweighted and survey-weighted 2.5th–97.5th reference intervals of PTH were 21.8–65.0 pg/mL and 20.5–67.7 pg/mL, respectively, when vitamin D status and serum calcium, magnesium, and phosphate levels were not considered.
conclusionsFuture population-based studies incorporating broader age ranges and comprehensive biochemical profiling are needed to refine population- and assay-specific PTH reference intervals and to clarify their implications for bone health. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.